Search research articles
Contact Us
Filters
Showing results (21-30 of 43) with videos related to
Page
of 5
Sort By:
Journal of Drugs in Dermatology : JDD
|
December 4, 2024
INDIVIDUAL ARTICLE: USCOM IV Algorithm for the Prevention and Management of Targeted Therapy-Related Cutaneous Adverse Events
Jonathan Leventhal, Ana Sofia Acosta Madiedo, Anneke Andriessen, et al.
Journal of Drugs in Dermatology : JDD
|
September 7, 2021
US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm
Mario E Lacouture, Jennifer Choi, Alice Ho, et al.
Journal of Drugs in Dermatology : JDD
|
November 9, 2023
INDIVIDUAL ARTICLE: USCOM Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events
Alana Deutsch, Mario Lacouture, Anneke Andriessen, et al.
Journal of the National Medical Association
|
March 24, 2022
Cancer healthcare disparities among African Americans in the United States
Edith Mitchell, Olatunji B Alese, Clayton Yates, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 25, 2010
Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer
J Randolph Hecht, Edith Mitchell, Marcus A Neubauer, et al.
Diseases of the Colon and Rectum
|
April 12, 2003
Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma
David E Stein, Najjia N Mahmoud, Pramila Rani Anné, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study
Charles S Fuchs, John Marshall, Edith Mitchell, et al.
Clinical Colorectal Cancer
|
July 16, 2008
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone
Daniel J Freeman, Todd Juan, Maureen Reiner, et al.
Plos One
|
January 25, 2012
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
Daniel A Monti, Edith Mitchell, Anthony J Bazzan, et al.
Anticancer Research
|
October 30, 2004
Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy
Mona Charara, Tina Bocker Edmonston, Susan Burkholder, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 43) with videos related to
Sort By:
Page
of 5
Journal of Drugs in Dermatology : JDD
|
December 4, 2024
INDIVIDUAL ARTICLE: USCOM IV Algorithm for the Prevention and Management of Targeted Therapy-Related Cutaneous Adverse Events
Jonathan Leventhal, Ana Sofia Acosta Madiedo, Anneke Andriessen, et al.
Journal of Drugs in Dermatology : JDD
|
September 7, 2021
US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm
Mario E Lacouture, Jennifer Choi, Alice Ho, et al.
Journal of Drugs in Dermatology : JDD
|
November 9, 2023
INDIVIDUAL ARTICLE: USCOM Algorithm for the Prevention and Management of Cutaneous Immunotherapy-Related Adverse Events
Alana Deutsch, Mario Lacouture, Anneke Andriessen, et al.
Journal of the National Medical Association
|
March 24, 2022
Cancer healthcare disparities among African Americans in the United States
Edith Mitchell, Olatunji B Alese, Clayton Yates, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 25, 2010
Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer
J Randolph Hecht, Edith Mitchell, Marcus A Neubauer, et al.
Diseases of the Colon and Rectum
|
April 12, 2003
Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma
David E Stein, Najjia N Mahmoud, Pramila Rani Anné, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study
Charles S Fuchs, John Marshall, Edith Mitchell, et al.
Clinical Colorectal Cancer
|
July 16, 2008
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone
Daniel J Freeman, Todd Juan, Maureen Reiner, et al.
Plos One
|
January 25, 2012
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer
Daniel A Monti, Edith Mitchell, Anthony J Bazzan, et al.
Anticancer Research
|
October 30, 2004
Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy
Mona Charara, Tina Bocker Edmonston, Susan Burkholder, et al.
Page
of 5